Company Overview

Conavi Medical Corp. is a Canadian medical technology company focused on cardiovascular imaging solutions used in interventional cardiology procedures. The company develops and commercializes hybrid intravascular imaging systems that combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) technologies into a single platform to support the diagnosis and treatment of coronary artery disease. Conavi operates within the broader medical device, cardiovascular imaging, and interventional healthcare technology industries.

The company’s primary commercial platform is the Novasight Hybrid System, which is designed to provide physicians with detailed imaging of coronary arteries during minimally invasive procedures. Revenue generation has historically been tied to system placements, imaging catheters, and related procedural products and collaborations. Conavi’s strategic positioning is centered on offering dual-modality imaging capabilities in a market where many competitors provide only a single imaging technology. The company traces its origins to research and technology development in Canada focused on advanced intravascular imaging and has evolved into a publicly traded cardiovascular device developer listed on the TSX Venture Exchange under the symbol CNVI.

Business Operations

Conavi Medical’s operations are primarily concentrated in cardiovascular imaging technologies for catheter-based coronary interventions. The company’s core business activities include research and development, regulatory advancement, commercialization, and clinical support for its imaging systems and related disposable products. Its flagship operating platform, the Novasight Hybrid System, integrates IVUS and OCT imaging into a single console and catheter workflow intended to improve procedural visualization for physicians performing coronary interventions.

The company operates primarily from Canada while pursuing commercial and strategic activities in the United States, where the interventional cardiology market represents a major growth opportunity. Conavi has engaged with hospitals, clinical research institutions, and industry collaborators to support product validation and market adoption. Public disclosures indicate that the company has pursued strategic relationships and commercialization partnerships tied to imaging technology deployment, though some details regarding long-term distribution scale and commercial penetration remain limited in publicly available filings. Data regarding certain partnership economics is inconclusive based on available public sources.

Strategic Position & Investments

Conavi Medical’s strategic direction has focused on expanding adoption of hybrid intravascular imaging technologies and strengthening its position in image-guided cardiovascular interventions. The company has emphasized clinical validation, regulatory progress, and commercial expansion initiatives aimed at increasing physician adoption of hybrid imaging systems in coronary procedures. Management has publicly identified the integration of complementary imaging modalities into a unified workflow as a differentiating factor in a competitive cardiovascular imaging market.

The company has invested significantly in imaging software, catheter development, and system integration technologies associated with the Novasight Hybrid System platform. Conavi has also pursued capital markets financing and strategic corporate initiatives to support commercialization and product development activities. Its broader strategic emphasis includes participation in emerging trends toward precision-guided minimally invasive cardiovascular procedures and enhanced procedural imaging analytics. Public filings and investor materials do not indicate a large diversified subsidiary structure compared with larger multinational medical device companies.

Geographic Footprint

Conavi Medical is headquartered in Toronto, Canada, and its operational footprint is centered primarily in North America. The company’s commercialization and regulatory focus has included both Canada and the United States, with the U.S. market representing a major strategic priority because of its scale in interventional cardiology procedures and hospital-based cardiovascular care.

Although Conavi is smaller in scale than major global cardiovascular device manufacturers, it has sought international visibility through clinical collaborations, regulatory engagement, and participation in global cardiology conferences and industry events. Its technology platform is intended for use in advanced hospital and catheterization laboratory environments, particularly in developed healthcare markets with established interventional cardiology infrastructure.

Leadership & Governance

Conavi Medical’s leadership team is composed of executives with backgrounds in medical devices, cardiovascular technologies, healthcare commercialization, and corporate finance. The company’s governance approach has emphasized technology innovation, clinical evidence generation, and strategic capital allocation to support long-term commercialization objectives in the cardiovascular imaging market.

Key executives and leadership figures include:

• Thomas Looby – Chief Executive Officer
• Maliheh Jahangiri – Chief Financial Officer
• Dr. Randy AuCoin – Chief Medical Officer
• Dr. Ravi Kashyap – Founder and technology leader associated with the company’s imaging innovation initiatives

Management communications and public disclosures have consistently emphasized advancing image-guided cardiovascular care through integrated imaging technologies and expanding physician access to hybrid intravascular visualization tools. Certain executive role timelines and historical leadership transitions vary across public disclosures; however, the individuals listed above are consistently referenced in recent company materials and filings.